To demonstrate the efficacy of different doses of frexalimab in comparison with placebo and in addition to standard of care (SOC) on endogenous insulin secretion in participants (12-21 y.o.) with newly diagnosed T1D over a 52-week period
DRI17476 is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the safety, efficacy, and tolerability of frexalimab in participants with newly diagnosed T1D on insulin therapy: adults (18-35 y.o.)
Participants ages 12-35 who have been diagnosed with T1D and within 90 days of first dose of insulin -Ages 12-35 -T1D diagnosis according to ADA criteria -Initiated insulin dosing not longer than 90 days prior to screening -Up to date on routine vaccinations -Be willing to use contraception and avoid pregnancy for the duration of treatment and for 3 months following treatment -
Principal Investigator